Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study. / Sørensen, Jens Benn; Horvat, Pia; Rosenlund, Mats; Kejs, Anne Mette; Patel, Dony; Juarez-Garcia, Ariadna; Lacoin, Laure; Daumont, Melinda J.; Penrod, John R.; O'donnell, John C.; Brustugun, Odd Terje; Ekman, Simon.

I: Future Oncology, Bind 18, Nr. 2, 2022, s. 205-214.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Sørensen, JB, Horvat, P, Rosenlund, M, Kejs, AM, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, MJ, Penrod, JR, O'donnell, JC, Brustugun, OT & Ekman, S 2022, 'Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study', Future Oncology, bind 18, nr. 2, s. 205-214. https://doi.org/10.2217/fon-2021-0746

APA

Sørensen, J. B., Horvat, P., Rosenlund, M., Kejs, A. M., Patel, D., Juarez-Garcia, A., Lacoin, L., Daumont, M. J., Penrod, J. R., O'donnell, J. C., Brustugun, O. T., & Ekman, S. (2022). Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future Oncology, 18(2), 205-214. https://doi.org/10.2217/fon-2021-0746

Vancouver

Sørensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A o.a. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future Oncology. 2022;18(2):205-214. https://doi.org/10.2217/fon-2021-0746

Author

Sørensen, Jens Benn ; Horvat, Pia ; Rosenlund, Mats ; Kejs, Anne Mette ; Patel, Dony ; Juarez-Garcia, Ariadna ; Lacoin, Laure ; Daumont, Melinda J. ; Penrod, John R. ; O'donnell, John C. ; Brustugun, Odd Terje ; Ekman, Simon. / Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study. I: Future Oncology. 2022 ; Bind 18, Nr. 2. s. 205-214.

Bibtex

@article{7d1df2d5fc59457aa5031d88b5c1629c,
title = "Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study",
abstract = "Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.",
keywords = "I-O Optimise initiative, NSCLC, overall survival, registry, SCAN-LEAF, time trends, treatment",
author = "S{\o}rensen, {Jens Benn} and Pia Horvat and Mats Rosenlund and Kejs, {Anne Mette} and Dony Patel and Ariadna Juarez-Garcia and Laure Lacoin and Daumont, {Melinda J.} and Penrod, {John R.} and O'donnell, {John C.} and Brustugun, {Odd Terje} and Simon Ekman",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors.",
year = "2022",
doi = "10.2217/fon-2021-0746",
language = "English",
volume = "18",
pages = "205--214",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015)

T2 - SCAN-LEAF study

AU - Sørensen, Jens Benn

AU - Horvat, Pia

AU - Rosenlund, Mats

AU - Kejs, Anne Mette

AU - Patel, Dony

AU - Juarez-Garcia, Ariadna

AU - Lacoin, Laure

AU - Daumont, Melinda J.

AU - Penrod, John R.

AU - O'donnell, John C.

AU - Brustugun, Odd Terje

AU - Ekman, Simon

N1 - Publisher Copyright: © 2021 The Authors.

PY - 2022

Y1 - 2022

N2 - Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

AB - Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

KW - I-O Optimise initiative

KW - NSCLC

KW - overall survival

KW - registry

KW - SCAN-LEAF

KW - time trends

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85121582602&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0746

DO - 10.2217/fon-2021-0746

M3 - Journal article

C2 - 34784783

AN - SCOPUS:85121582602

VL - 18

SP - 205

EP - 214

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 2

ER -

ID: 318201523